Stock Analysis on Net
Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ) 

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Free Cash Flow to The Firm (FCFF)

Johnson & Johnson, FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 28, 2025 Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net earnings 26,804 14,066 35,153 17,941 20,878
Net noncash charges 10,444 8,363 (14,869) 7,264 6,770
Changes in assets and liabilities, net of effects from acquisitions and divestitures (12,718) 1,837 2,507 (4,011) (4,238)
Net cash flows from operating activities 24,530 24,266 22,791 21,194 23,410
Cash paid during the year for interest, net of amount capitalized, net of tax1 1,533 1,611 1,563 771 863
Interest expense capitalized, net of tax2 94 67 62 40 45
Additions to property, plant and equipment (4,832) (4,424) (4,543) (4,009) (3,652)
Free cash flow to the firm (FCFF) 21,325 21,520 19,873 17,996 20,666

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial information indicates fluctuations in both net cash flows from operating activities and free cash flow to the firm (FCFF) over the five-year period. While both metrics demonstrate overall stability, there are discernible shifts in their trajectories.

Net Cash Flows from Operating Activities
Net cash flows from operating activities experienced a decrease from US$23,410 million in 2021 to US$21,194 million in 2022. A subsequent recovery was observed in 2023, reaching US$22,791 million, followed by further increases to US$24,266 million in 2024 and US$24,530 million in 2025. This suggests a strengthening of core operational cash generation in the later years of the observed period.
Free Cash Flow to the Firm (FCFF)
FCFF mirrored the trend in operating cash flows, declining from US$20,666 million in 2021 to US$17,996 million in 2022. A recovery began in 2023, with FCFF reaching US$19,873 million. Continued growth was evident in 2024, with FCFF increasing to US$21,520 million, and remained relatively stable in 2025 at US$21,325 million. The FCFF trend closely follows the operating cash flow trend, indicating a strong correlation between the two.

The period between 2021 and 2022 shows a concurrent decrease in both operating cash flows and FCFF. The subsequent years demonstrate a consistent upward trend in both metrics, suggesting improved financial performance and cash generation capabilities. The stabilization of FCFF in 2025, while still at a healthy level, warrants monitoring to determine if this represents a plateau or a temporary pause in growth.

Relationship between Operating Cash Flow and FCFF
The difference between net cash flows from operating activities and FCFF remains relatively consistent across the observed period. This suggests that the factors impacting FCFF, beyond core operations, are also relatively stable. Further investigation into the components of this difference would be necessary to provide a more detailed understanding.

AI Ask an analyst for more



Interest Paid, Net of Tax

Johnson & Johnson, interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 28, 2025 Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Effective Income Tax Rate (EITR)
EITR1 17.70% 15.70% 11.50% 17.40% 8.30%
Interest Paid, Net of Tax
Cash paid during the year for interest, net of amount capitalized, before tax 1,863 1,911 1,766 933 941
Less: Cash paid during the year for interest, net of amount capitalized, tax2 330 300 203 162 78
Cash paid during the year for interest, net of amount capitalized, net of tax 1,533 1,611 1,563 771 863
Interest Costs Capitalized, Net of Tax
Interest expense capitalized, before tax 114 79 70 49 49
Less: Interest expense capitalized, tax3 20 12 8 9 4
Interest expense capitalized, net of tax 94 67 62 40 45

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 See details »

2 2025 Calculation
Cash paid during the year for interest, net of amount capitalized, tax = Cash paid during the year for interest, net of amount capitalized × EITR
= 1,863 × 17.70% = 330

3 2025 Calculation
Interest expense capitalized, tax = Interest expense capitalized × EITR
= 114 × 17.70% = 20


The period under review demonstrates fluctuations in both interest payments, net of tax, and the effective income tax rate. A notable increase in net interest paid is observed between 2021 and 2023, followed by relative stabilization in subsequent years. The effective income tax rate exhibits volatility, impacting the after-tax cost of debt.

Net Interest Paid
Cash paid for interest, net of tax, decreased from US$863 million in 2021 to US$771 million in 2022, representing a decline of approximately 10.7%. A substantial increase is then seen in 2023, rising to US$1,563 million, and continuing to US$1,611 million in 2024. The final year reviewed, 2025, shows a slight decrease to US$1,533 million. This suggests a period of increased borrowing or higher interest rates between 2022 and 2024, with a modest reduction in 2025.
Interest Expense Capitalized, Net of Tax
The amount of interest expense capitalized, net of tax, has generally trended upward. Starting at US$45 million in 2021, it increased to US$40 million in 2022, then rose steadily to US$62 million in 2023, US$67 million in 2024, and reaching US$94 million in 2025. This indicates a growing proportion of interest costs being deferred as part of asset acquisition or construction costs.
Effective Income Tax Rate (EITR)
The effective income tax rate experienced significant variation. It began at 8.30% in 2021, increased substantially to 17.40% in 2022, then decreased to 11.50% in 2023. A further increase to 15.70% occurred in 2024, followed by a rise to 17.70% in 2025. These fluctuations in the EITR would directly influence the after-tax amount of interest expense, contributing to the observed changes in net interest paid.

The combined effect of these factors suggests that while the underlying interest obligations have increased, the actual cash outflow is also influenced by the company’s tax position. The increasing capitalization of interest expense suggests a growing investment in long-term assets.

AI Ask an analyst for more



Enterprise Value to FCFF Ratio, Current

Johnson & Johnson, current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 645,609
Free cash flow to the firm (FCFF) 21,325
Valuation Ratio
EV/FCFF 30.27
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc. 25.61
Amgen Inc. 23.92
Bristol-Myers Squibb Co. 11.63
Danaher Corp. 27.07
Eli Lilly & Co. 117.85
Gilead Sciences Inc. 17.27
Merck & Co. Inc. 26.43
Pfizer Inc. 17.07
Regeneron Pharmaceuticals Inc. 19.10
Thermo Fisher Scientific Inc. 30.87
Vertex Pharmaceuticals Inc. 35.76
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 30.32
EV/FCFF, Industry
Health Care 28.77

Based on: 10-K (reporting date: 2025-12-28).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.



Enterprise Value to FCFF Ratio, Historical

Johnson & Johnson, historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 28, 2025 Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 608,279 390,710 383,498 428,242 439,101
Free cash flow to the firm (FCFF)2 21,325 21,520 19,873 17,996 20,666
Valuation Ratio
EV/FCFF3 28.52 18.16 19.30 23.80 21.25
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc. 23.29 20.05 14.89 12.15 13.18
Amgen Inc. 23.08 15.35 22.22 16.01 15.82
Bristol-Myers Squibb Co. 10.84 9.94 9.14 13.87 10.52
Danaher Corp. 29.01 28.93 36.34 25.74 28.25
Eli Lilly & Co. 107.04 200.96 655.43 59.17 38.39
Gilead Sciences Inc. 19.36 14.50 13.41 13.58 8.42
Merck & Co. Inc. 25.30 13.24 37.84 19.09 23.27
Pfizer Inc. 18.08 15.33 32.24 9.15 8.40
Regeneron Pharmaceuticals Inc. 20.01 19.97 25.33 23.31 9.81
Thermo Fisher Scientific Inc. 28.42 26.13 28.85 31.61 33.14
Vertex Pharmaceuticals Inc. 36.94 29.45 16.68 22.47
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 28.89 23.59 27.29 18.08 16.12
EV/FCFF, Industry
Health Care 27.34 24.05 25.98 18.66 17.80

Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 See details »

2 See details »

3 2025 Calculation
EV/FCFF = EV ÷ FCFF
= 608,279 ÷ 21,325 = 28.52

4 Click competitor name to see calculations.


The Enterprise Value to Free Cash Flow to the Firm (EV/FCFF) ratio exhibits fluctuations over the observed period. Initially, the ratio increased, followed by a decrease, and then a substantial rise in the most recent year.

Enterprise Value (EV)
Enterprise Value decreased from US$439,101 million in 2021 to US$428,242 million in 2022, representing a decline of approximately 2.5%. A further decrease was noted in 2023, falling to US$383,498 million. A modest increase occurred in 2024, reaching US$390,710 million, before a significant jump to US$608,279 million in 2025.
Free Cash Flow to the Firm (FCFF)
Free Cash Flow to the Firm experienced a decrease from US$20,666 million in 2021 to US$17,996 million in 2022, a reduction of roughly 12.7%. FCFF then recovered to US$19,873 million in 2023 and continued to rise to US$21,520 million in 2024. In 2025, FCFF remained relatively stable at US$21,325 million, showing a slight decrease from the prior year.
EV/FCFF Ratio
The EV/FCFF ratio increased from 21.25 in 2021 to 23.80 in 2022, indicating a less favorable valuation based on free cash flow. The ratio subsequently decreased to 19.30 in 2023 and further to 18.16 in 2024, suggesting an improving valuation. However, the ratio experienced a substantial increase to 28.52 in 2025, driven primarily by the significant rise in Enterprise Value, indicating a considerably higher valuation relative to free cash flow generation in that year.

The observed trend suggests that while the firm’s ability to generate free cash flow has been relatively stable, changes in the market’s assessment of the firm’s overall value, as reflected in Enterprise Value, have had a more pronounced impact on the EV/FCFF ratio. The substantial increase in the ratio in 2025 warrants further investigation to understand the underlying drivers of the increased Enterprise Value.

AI Ask an analyst for more